|Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 ...|
GBI Research, the leading business intelligence provider, has released its latest research,'Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact ...
PR Newswire (press release) - Wed, 23 Apr 2014 10:15
|FDA Approves Ramucirumab for Gastric and GEJ Adenocarcinoma|
The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) as a treatment for patients with unresectable gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy, based on a ...
OncLive - Mon, 21 Apr 2014 17:22
|US FDA approves Lilly's Cyramza to treat advanced gastric cancer after prior ...|
pharmabiz.com - Tue, 22 Apr 2014 20:32
|New Gastric Cancer Drug Gets FDA Approval|
Monthly Prescribing Reference - Mon, 21 Apr 2014 14:02
|Breaking News: Gastric Cancer Drug Approved|
Drug Discovery & Development - Tue, 22 Apr 2014 06:07
|Lilly announces FDA approval of new cancer treatment|
Fox 59 - Mon, 21 Apr 2014 23:56
|Cyramza approved by FDA for stomach cancer|
Oncology Nurse Advisor - Tue, 22 Apr 2014 09:30
|Lilly's CYRAMZA™ (ramucirumab) Becomes First FDA-Approved Treatment for ...|
MarketWatch - Mon, 21 Apr 2014 18:19
|Ganetespib trial hints at survival benefit in lung adenocarcinoma|
Tested in combination with docetaxel, the experimental drug appeared to improve overall and progression-free survival, compared with docetaxel alone, as second-line therapy for patients with advanced non–small cell adenocarcinoma of the lung, Dr ...
The Oncology Report - Mon, 21 Apr 2014 13:15
|Research and Markets: Global Pancreatic Adenocarcinoma Therapeutics in ...|
The current Pancreatic Cancer (PC) therapeutics market is very limited, with only four drugs approved for the treatment of the disease. These are the generics gemcitabine and fluorouracil (5-FU) and the patented drugs Tarceva, by Genentech and Roche ...
Business Wire (press release) - Tue, 22 Apr 2014 06:15
|Pancreatic Adenocarcinoma Therapeutics Market Analysis & 2019 Forecasts|
Dallas, TX -- (SBWIRE) -- 04/21/2014 -- RnRMarketResearch.com adds new market research report “Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 – Early Stage Pipeline Shows Diversity of Novel Targets though Commercial ...
DigitalJournal.com - Mon, 21 Apr 2014 10:48
|Survival greater in esophageal adenocarcinoma patients previously diagnosed ...|
The small proportion of patients with esophageal adenocarcinoma previously diagnosed with Barrett's esophagus exhibited improved survival compared with those without a previous diagnosis in a recent study. Researchers in Northern Ireland conducted a ...
Healio - Thu, 10 Apr 2014 07:26
|Acute pancreatitis may be predictor of pancreatic adenocarcinoma|
Many patients with pancreatic adenocarcinoma initially presented with an episode of acute pancreatitis, and as long as 2 years elapsed between diagnoses, according to results of a retrospective study. The correlation appeared particularly strong in ...
Healio - Tue, 25 Mar 2014 07:03
|Global Pancreatic Adenocarcinoma Therapeutics Market to Reach $1.2 billion in ...|
Pancreatic Adenocarcinoma Therapeutics Market in Major Developed Markets to 2019 is a new pharma report announced by Reportstack. This report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers ...
WhaTech - Mon, 07 Apr 2014 14:02